After eviCore suggested that Exact Sciences' Cologuard may be considered for colorectal cancer screening once every three years, Craig-Hallum analyst Bill Bonello says he believes that at least one large health insurer, Highmark, has already elected to follow this policy. The analyst continues to believe that Cologuard will receive broad commercial payer coverage in light of the 2016 USPSFT final colorectal cancer screening recommendation and that increased payer coverage will drive increased test volumes. He reiterates a Buy rating and $26 price target on the shares.